Abstracts tagged "biomarkers and rheumatoid arthritis"

Abstract Number: 568 • 2016 ACR/ARHP Annual Meeting
Triggering Receptor Expressed on Myeloid Cells (TREM) As a Novel Indicator of Disease Progression in ‘at-Risk’ Individuals
Laura Hunt¹, Sahar Musaad^1,2, John Stephenson³, Becki Burn², Isao Matsuura¹, Kulveer Mankia¹, Jackie L. Nam¹ and Paul Emery¹, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Microbiology, Calderdale & Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom, ³Department Health Sciences, University of Huddersfield, Huddersfield, United Kingdom
Background/Purpose: Whilst the exact aetiology of rheumatoid arthritis (RA) remains unclear, current concepts suggest an environmental link with possible microbial triggers. Studying individuals at-risk of…
Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting
Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Ryan Davis¹, Pooja Naik¹, Maximilian Konig¹ and Felipe Andrade¹, ¹Department of Medicine, Division of Rheumatology, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ²Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY
Background/Purpose: The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…
Abstract Number: 483 • 2015 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis
Ted R. Mikuls¹, Brian Coburn¹, Harlan Sayles², Fang Yu³, Mary Brophy⁴, James R. O'Dell¹, Lynell W. Klassen⁵ and Geoffrey M. Thiele¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Public Health, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Heathcare System, Boston, MA, ⁵Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous reports have demonstrated that malondialdehyde-acetaldehyde (MAA) adducts are produced as a byproduct of oxidative stress and lipid peroxidation and are expressed in…
Abstract Number: 590 • 2015 ACR/ARHP Annual Meeting
Expression Levels of Selected Genes May Predict Response to TNF Alpha Blockers or Rituximab in the Individual Rheumatoid Arthritis Patient
Daphna Paran¹, Shlomo Pundak², Yaniv Kotler², Yoav Smith³, Uri Arad⁴, David Levartovsky⁵, Ilana Kaufman⁴, Victoria Furer⁴, Ofir Elalouf⁴, Adi Broyde¹, Sara Pel⁴, Dan Caspi⁴ and Ori Elkayam⁴, ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Genefron Ltd. Jerusalem Israel, Jerusalem, Israel, ³Genomic Data analysis Hadassah Medical School Hebrew University, Jerusalem Israel, Jerusalem, Israel, ⁴Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁵Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Background/Purpose: Patients with Rheumatoid arthritis (RA) have a variety of therapeutic options however tools to predict individual patients' response are limited. The purpose of this…
Abstract Number: 1307 • 2013 ACR/ARHP Annual Meeting
Synovial Subset–Derived Baseline Serum Biomarkers Segregate Rheumatoid Arthritis Patients Into Subgroups With Distinct Serum Protein and Clinical Characteristics
A. Francesca Setiadi, Nicholas Lewin-Koh, Sarah Kummerfeld, David F. Choy, Cécile T.J. Holweg, Sally Fischer, An Song and Michael J. Townsend, Genentech, South San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease. Predictive biomarkers have the potential to enhance treatment effectiveness by enabling identification of likely responders to a…
Abstract Number: 2576 • 2012 ACR/ARHP Annual Meeting
Production of Citrullinated Filaggrin-Specific IgG in Rheumatoid Arthritis Patients Is Associated with an Expansion of Citrullinated Filaggrin Tetramer-Binding Switched Memory Blood B Cells
Philip Titcombe¹, Laura O. Barsness¹, Lauren Giacobbe¹, Emily Baechler Gillespie¹, Erik J. Peterson² and Daniel L. Mueller², ¹University of Minnesota Medical School, Minneapolis, MN, ²Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: Rheumatoid Arthritis (RA) is highly associated with the production of autoantibodies, including rheumatoid factors and anti-citrullinated protein antibodies (ACPA). It remains uncertain whether production…
Abstract Number: 427 • 2012 ACR/ARHP Annual Meeting
Epigenetic Features As Predictive Markers of Responsiveness to Epitope-Specific Therapy in Rheumatoid Arthritis
Roberto Spreafico¹, Maura Rossetti¹, Theodorus Van Der Broek¹, Olivia Morrow¹ and Salvatore Albani², ¹Translational Immunology, Sanford-Burnham Medical Research Institute, La Jolla, CA, ²Translational Research Program, Infectious and Inflammatory Diseases, Sanford-Burnham Medical Research Institute, La Jolla, CA
Background/Purpose: The focus of current research for new therapeutic approaches in Rheumatoid arthritis (RA) is shifting from mere suppression to induction and maintenance of tolerance.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].